i have never seen modulation for the good of the entire world in big pharmas. Only when some 3rd world country questions their patent then they start to adjust prices to more reasonable level (panic i guess?), not cause of the greater good, yet just to keep market share at any price.
China's hcv market must be soooo tempting for Gilead (20mil infected?), but i wonder how will they approach it. In India Abbott certainly had it rough with Ritnovir (reduced price of 240$ per month was too expensive for India). My prediction, Gilead will take the "cream" with western countries first (2-3 years), then hit China and India with reduced price...of course competition is a big factor too. It's gonna be interesting period to watch the greed game fall appart bit by bit.
Matt Chris said
Nov 24, 2013
Hey Zlikster
That was a great article in your link, I hope that organization has its way with it's patent opposition. Gilead will still make a killing with the other countries.
Gilead has allready proven its board of directors are quite greedy so hopefully this will burst their bubble. The whole pricing arrangement of these new DAA's needs to modulate lower for the good of the entire world, so the more competition the better.
considering how Abbott lost battle with it's patent on Ritonavir in India, who knows, maybe we folks who can't afford 80k $ for 90-180 pills of Sofosbuvir can obtain em soon at affordable price from India directly?
we can only hope. Until that happens, somewhere before year 2029 sounds like good estimation for affordable Sofosbuvir sold in Bosnia.
China's hcv market must be soooo tempting for Gilead (20mil infected?), but i wonder how will they approach it. In India Abbott certainly had it rough with Ritnovir (reduced price of 240$ per month was too expensive for India). My prediction, Gilead will take the "cream" with western countries first (2-3 years), then hit China and India with reduced price...of course competition is a big factor too. It's gonna be interesting period to watch the greed game fall appart bit by bit.
Hey Zlikster
That was a great article in your link, I hope that organization has its way with it's patent opposition. Gilead will still make a killing with the other countries.
Gilead has allready proven its board of directors are quite greedy so hopefully this will burst their bubble. The whole pricing arrangement of these new DAA's needs to modulate lower for the good of the entire world, so the more competition the better.
matt
http://www.msfaccess.org/about-us/media-room/press-releases/gilead-attempt-secure-patent-hepatitis-c-drug-opposed-india
considering how Abbott lost battle with it's patent on Ritonavir in India, who knows, maybe we folks who can't afford 80k $ for 90-180 pills of Sofosbuvir can obtain em soon at affordable price from India directly?
we can only hope. Until that happens, somewhere before year 2029 sounds like good estimation for affordable Sofosbuvir sold in Bosnia.
best